← boardnext 2026-09-30next 2026-10next 2026-11next 2027-05next 2027-05-25next 2027-06-01next 2027-09-02next 2028-02next 2029-12-31
IBRX
ImmunityBio, Inc.distress 5/10 · elevated risk$7.42-1%today-36% from 52w high
Oncology 3Infectious Disease 1
Lead: Pancreatic Cancer · target PD-L1 · est. market ~$5B (approx, global)
Revenue
$44M
Liquidity
$381M
Runway
1.3 yrs
Shares 1y
+11%
Price & events
+1.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
-0.4%
1W
+1.4%
1M
-9.4%
3M
+15.0%
6M
+148.2%
1Y
+31.3%
2Y
-31.4%
5Y
-46.0%
All
Overview
- Market Cap
- $7.77B
- Volume
- 553.83K
- 52 Week Range
- $1.98 – $11.55
- Total Shares
- 1.05B
- Float Shares
- 394.16M
- Short %
- 33.94%
- % Held by Insiders
- 62.47%
- % Held by Institutions
- 17.66%
- RVOL
- 0.05x
- Beta
- 0.08
Pipeline stages · 12 programs
BCG (50mg/instillation), N-803 (400 μg/instillation)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
N-803 (IL-15 Superagonist)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
N-803, Pembrolizumab, Nivolumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Gemcitabine, N-803, M-CENK
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CD19 t-haNK
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Nogapendekin alfa inbakicept (NAI)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Intravesical Recombinant Mycobacterium (rMBCG)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Bevacizumab, PD-L1 t-haNK, N-803
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Anktiva
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 12 programs · 2 more ▾
HCW9218, Gemcitabine (GEM), Nab-paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
N803, CD19t-haNK suspension, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 20 trials · 16 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-30 Estimated 50% readout ~2026-11-14 | Phase 1/2 | BCG (50mg/instillation), N-803 (400 μg/instillation) | Non-muscle Invasive Bladder Cancer | — | active not recruiting |
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 2 | N-803 (IL-15 Superagonist) | Long COVID | — | recruiting |
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | N-803 and BCG, N-803 and Gemcitabine | Non-muscle Invasive Bladder Cancer (NMIBC) | — | not yet recruiting |
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 2 | Gemcitabine, N-803, M-CENK | Platinum-resistant Ovarian Cancer | — | recruiting |
| 2027-05-25 Estimated 50% readout ~2027-07-09 | Phase 2 | CD19 t-haNK- IV Administration | Relapsed B-Cell Non Hodgkin Lymphoma | — | recruiting |
Show all 20 trials · 15 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06-01 Estimated 50% readout ~2027-07-01 | Phase 1 | Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101) | Pancreatic Cancer Resectable, Pancreatic Cancer | — | not yet recruiting |
| 2027-08-03 Estimated 50% readout ~2027-09-17 | Phase 2 | Nogapendekin alfa inbakicept (NAI) | Sepsis, Septic Shock, Lymphopenia, Immunosuppression, Critical Illness | — | not yet recruiting |
| 2027-09-02 Estimated 50% readout ~2027-10-02 | Phase 1 | IBRX-042 | HPV-Related Carcinoma | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | CD19 t-haNK- IV Administration, N-803, rituximab | Relapsed B-Cell Non-Hodgkin Lymphoma | — | not yet recruiting |
| 2028-02 Estimated 50% readout ~2028-03-17 | Phase 1/2 | Intravesical Recombinant Mycobacterium (rMBCG) | NMIBC | — | recruiting |
| 2028-03 Estimated 50% readout ~2028-03-31 | Phase 1 | CD19 t-haNK | Non-Hodgkin Lymphoma Refractory/ Relapsed | — | recruiting |
| 2028-09 Estimated 50% readout ~2028-11-15 | Phase 3 | N-803, Tislelizumab, Docetaxel | NSCLC Stage IV | — | recruiting |
| 2028-12 Estimated 50% readout ~2028-12-31 | Phase 1 | CD19 t-haNK | B-ALL, Leukemia | — | recruiting |
| 2029-08-31 Estimated 50% readout ~2029-10-15 | Phase 2 | N-803, Pembrolizumab, Nivolumab | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | — | active not recruiting |
| 2029-12-31 Estimated 50% readout ~2030-02-14 | Phase 2 | Bevacizumab, PD-L1 t-haNK, N-803 | Glioblastoma | — | active not recruiting |
| 2030-12-31 Estimated 50% readout ~2031-02-14 | Phase 2 | Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel | HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer | — | not yet recruiting |
| 2026-07-01 | Phase 2 | Anktiva | Long COVID, Long COVID Syndrome, Long Covid 19 | — | recruiting |
| 2026-05-15 | Phase 1 | N803, CD19t-haNK suspension, Cyclophosphamide | Non Hodgkin's Lymphoma Refractory/Relapsed | 20 | recruiting |
| 2025-10-13 | Phase 2 | N-803, Aldoxorubicin HCl, PD-L1 t-haNK | Pancreatic Cancer | 328 | active not recruiting |
| 2025-02-15 | Phase 1/2 | HCW9218, Gemcitabine (GEM), Nab-paclitaxel | Advanced Pancreatic Carcinoma | 21 | completed |
Catalyst news & presentations · 9
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- May 16, 2026 at 1:30 p.m. EDTconferencedata presentationsecondaryTokyo-172 BCG, ANKTIVA · Dr. Soon-Shiong presents at AUA 2026 on IL-15 and BCG updates.SEC 8-K
- 2026-05-14partnershipTokyo-172 BCG · Exclusive U.S. development and supply agreement with Japan BCG Laboratory.SEC 8-K
- 2026-03-30partnershipAmended Revenue Interest Purchase Agreement with Oberland Capital for $75M additional capitalSEC 8-K
- 2026-03-30partnershipNant Capital converted $25M promissory note to equitySEC 8-K
- 2026-03-13warning letterANKTIVA · FDA OPDP issued warning letter regarding promotional materials for ANKTIVA; company submitted response and corrective actionsSEC 8-K
- 2025-05-02refuse to fileANKTIVA · FDA issued a refusal to file letter for the sBLA of ANKTIVA plus BCG in BCG-unresponsive NMIBC papillary indication.SEC 8-K
- 2025-04-07partnershipSecurities purchase agreement for $75M registered direct offering of common stock and warrants with institutional investorSEC 8-K
- on or about December 12, 2024trial initiationsecondaryClosing of public offering of common stockSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-02HC Wainwright & Co.Buy
- 2026-05-21BTIGBuy
- 2026-05-20HC Wainwright & Co.Buy
- 2026-05-05D. Boral CapitalBuy
- 2026-04-21D. Boral CapitalBuy
- 2026-04-08D. Boral CapitalBuy
Competitors — PD-L1
Recent news
- 2026-07-22Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
- 2026-07-22IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
- 2026-07-20ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
- 2026-07-20ImmunityBio: Revisiting My Bearish Call After A 250% Rise (Upgrade) (NASDAQ:IBRX) - Seeking Alpha
- 2026-07-18ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound - TechStock²
- 2026-07-18IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
- 2026-07-18ImmunityBio (IBRX) Could Be 41% Below Fair Value After Anktiva Optimism - Sahm
- 2026-07-17ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy (NASDAQ:IBRX) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.